Sputnik-Light is just one step away from registering as the single-dose Covid-19 vaccine
The Russian government claimed last week that clinical trials of the single-dose Covid-19 vaccine had been completed. Sputnik-Light. According to the Russian news agency TASS, the Russian Ministry of Health indicated that it is only one step away from registering as a new version. Which could become a possible temporary solution in the fight against the pandemic in countries with high infection rates.
Moscow reported that its two-dose Sputnik V vaccine will remain the main version used in Russia. Since its effectiveness achieved the 92% effective.
The Gamaleya National Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation issued a statement on the progress of the doses. Showing in conjunction with the Russian Direct Investment Fund (RDIF), which currently has 40 thousand volunteers participating in phase III clinical trials. These are randomly controlled with placebos. Of which more than 20,000 have already been vaccinated with the first dose of the antidote. And more than sixteen thousand with the first and second applications.
In turn, the Minister of Health of Russia, Mikhail Murashko, He was also very optimistic for the next few months. The use of the Sputnik-Light vaccine and the results of clinical trials showing that it is an effective solution. Mostly to stop the spread of coronavirus infection and an alternative healthcare tool.
Sputnik V vaccine to be produced in china
The Russian authorities agreed with the Chinese company Shenzhen Yuanxing Gene-tech the production of 60 million drugs of the Russian antidote Sputnik V. This was reported this Monday in a statement by the Fund for Direct Investments of Russia (FIDR).
The document indicates that FIDR and one of China's leading biotechnology companies have agreed to cooperate for the production of 60 million doses. So far it is only the first registered vaccine against the coronavirus in the world, therefore, the Sputnik-Light version has yet to wait.
The fund, in charge of promoting the sale of Sputnik V, specifies that the agreement will allow vaccinating more than 30 million people. He anticipates that the start of commercial production is expected in May ”, adds the Russian Direct Investment Fund.
Due to its wide application worldwide, until now, the Sputnik V It has been recorded in 57 countries with a total population of 1.5 billion people. As stated in an interview with Alexandr Ginzburg, director of the Russian Gamaleya Research Center that developed the antidote. Who also informed that the manufacturers of the preparation want to supply it “to another 50 countries. And that the new version Sputnik-Light, is expected as a possible success that can reduce the levels of contagion and mortality in many countries of the world.